Scientists have identified a molecular mechanism through which an oral bacterium accelerates colorectal cancer growth.
Tests have shown that around a third of people who develop colorectal cancer also have the bacterium, which has the name Fusobacterium nucleatum. Their cancer also tends to be more aggressive, but it was not clear why until the recent study.
A paper that now features in the journal EMBO Reports reveals how the microorganism promotes the growth of cancer cells but not that of noncancerous cells.
The findings should help to clarify why some colorectal cancers develop much faster than others, say the researchers who hail from Columbia University in the City of New York.
The team also identified a protein that could form the basis of a test for more aggressive cancers and could lead to new treatments for colorectal and other cancers.
At the start of 2016, there were approximately 1.5 million people in the U.S. with a history of colorectal cancer, some of whom were cancer free.
Colorectal cancer develops from uncontrolled growth and survival of abnormal cells in the colon or rectum, which are the final sections of the digestive, or gastrointestinal, tract.
The colon absorbs water and nutrients from what is left of food after it has traveled through the stomach and small intestine. It then passes the remaining waste to the rectum, which stores it ready for expulsion through the anus.
The most common precancerous stage of colorectal cancer is a polyp, which is a growth that develops in the tissue that lines the colon and rectum. Polyps grow very slowly, sometimes taking 20 years to develop.
Most polyps develop from cells that make up the glands that produce a lubricating mucus in the colon and rectum. For this reason, they have the name adenomatous polyps, or adenomas.
Adenomas are very common, and around 33–50 percent of people will develop at least one. However, while they can all become cancerous, less than 10 percent actually become invasive.
Scientists have known for some time that the abnormal cells that lead to cancerous adenomas in colorectal cancer arise because of genetic mutations that build up over time.
However, more recently, they have increasingly observed that F. nucleatum, which often occurs in tooth decay, also plays a significant role.
“Mutations,” says senior study author Yiping W. Han, who is a professor of microbial sciences in the College of Dental Medicine, “are just part of the story.”
“Other factors, including microbes, can also play a role,” she adds.
In previous work, Prof. Han and her team found that F. nucleatum produces the molecule FadA adhesin, which sets off a series of molecular events in colon cells that scientists have linked to a number of cancers.
That work also revealed that the protein only has this effect in cancerous colon cells — it does not trigger these events in healthy colon cells.
Prof. Han says that the goal of the more recent study was to “find out why F. nucleatum only seemed to interact with the cancerous cells.”
The researchers started the new work by studying noncancerous colon cells in culture. They saw that these did not make the protein Annexin A1, which promotes growth in cancer cells.
Further tests in cell cultures and in mice revealed that blocking the protein stopped F. nucleatum from being able to attach to cancer cells, which stopped them growing so fast.
Another set of tests also revealed that the microbe stimulates cancer cells to make more Annexin A1, which in turn attracts more F. nucleatum.
“We identified a positive feedback loop that worsens the cancer’s progression,” Prof. Han explains. The cancer cells make Annexin A1 that then attracts F. nucleatum, the effect of which is to spur them to produce more of the protein.
“We propose a two-hit model, where genetic mutations are the first hit. F. nucleatum serves as the second hit, accelerating the cancer signaling pathway and speeding tumor growth.”
Prof. Yiping W. Han
The research team’s search of a national database yielded records on 466 people with molecular details about their primary colon cancer. The researchers found that those with higher levels of Annexin A1 fared worse, no matter what their gender, age, or cancer grade and stage.
The team intends to explore how to use Annexin A1 as a marker for identifying aggressive colorectal cancer. There might also be opportunities for new treatments for colorectal and other cancers that target the protein.